Abstract:
Release Date: June 1, 2009
Expiration Date: June 30,2010
Estimated Time to Compete Activitiy: 1 hour
Sponsors:
This activity is jointly sponsored by Postgraduate Institute for Medicine and IMPACt, Inc.
Contact Postgraduage Institute for Medicine
Commercial Support:
This activity is supported by an educational grant from Eli Lilly and Company.
Description:
"Virtual Breast Tumor Board: Neoadjuvant Challenges" is a case-based discussion that focuses on current issues and changing dynamics in the treatment of breast cancer patients using neoadjuvant therapies. The panel of experts will discuss the most appropriate management options for the cases and emphasize a multidisciplinary team approach to treatment.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the indications and contraindications to neoadjuvant therapy in operable breast cancer
- Discuss emerging and new clinical trial data for neoadjuvant systemic breast cancer therapy
- Cite controversies in performing sentinel node biopsy after vs. before neoadjuvant systemic therapy
- Identify novel cytotoxic and targeted agents and their utility in neoadjuvant regimens
Target Audience:
This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists and surgeons who care for patients with breast cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and IMPACt, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
Introduction
45 year old female in good health, no family history of breast cancer presents with a 3cm clinically node negative tumor in the UIQ of a small B cup breast.
52 year old presents with a 4.5cm mass in the LIQ of the breast. Mammogram confirms a unicentric mass and demonstrates a dense enlarged axillary node. Ultrasound confirms an enlarged axillary node.
Questions and Answers
Faculty:
Monica Morrow, MD, FACS (Course Director)
Chief, Breast Surgery Service, Anne Burnett Windfohr Chair of Clinical Oncology
Memorial Sloan-Kettering Cancer Center
Ruth O’Regan, MD
Associate Professor of Hematology and Medical Oncology
Director, Translational Breast Cancer Research Program
Director, Hematology and Medical Oncology Fellowship Program
Emory Winship Cancer Institute
Jay R. Harris, MD
Chair, Department of Radiation Oncology
Dana Farber Cancer Institute
Professor of Radiation Oncology
Harvard Medical School
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Monica Morrow, MD
No significant financial relationship with any commercial entity related to this activity
Jay R. Harris, MD
No significant financial relationship with any commercial entity related to this activity
Ruth O’Regan, MD
Consulting fees: Genentech
Speakers’ Bureau: Eli Lilly and Company, Genentech, Pfizer
The following PIM and IMPACt, Inc. clinical content reviewers, Linda Graham, RN, Jan Hixon, RN, Trace Hutchison, PharmD and Scott McMahon hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity or any amount during the past 12 months.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.